Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Scaling next-generation microencapsulation to industrial maturity (KAPSCALE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: CLOSED

KAPSERA is a French deeptech startup which has developed a breakthrough microencapsulation technology based on scalable microfluidics. Its patented process produces natural, food-grade alginate microcapsules with a liquid core, enabling the protection and controlled release of fragile natural active ingredients such as microorganisms, enzymes, pheromones, or vitamins. This innovation addresses a major technological gap in the agri-food industry, where current encapsulation methods are either too costly, not scalable, or reliant on non-biodegradable polymers soon restricted by EU regulations. The KAPSCALE project aims to bring KAPSERA’s process to industrial maturity, scaling production from pilot to 1 000 tons per year and paving the way for European and global deployment. The project will strengthen Europe’s bioeconomy by providing manufacturers across the farm-to-fork value chain - from agriculture to animal and human nutrition - with a sustainable alternative to synthetic additives and microplastics. KAPSCALE will combine industrial scale-up, process optimization, and market validation through strategic partnerships with leading agri-food companies. Its ambition is to position KAPSERA as the European leader in natural microencapsulation by 2030, operating industrial units for third parties and generating more than €35 million in annual revenues. Beyond its economic potential, the project will generate over 50 qualified jobs by 2027, foster sustainable agriculture and nutrition, and contribute directly to the EU Green Deal objectives by reducing chemical inputs, microplastic pollution, and greenhouse gas emissions across the value chain, creating a safer, more sustainable, and healthier future from field to plate.

Keywords: microencapsulation,natural active ingredients,agriculture feed food applications,microfluidics,industrial scale up,coextrusion jetting,enabling formulation technology,sustainability,alginate
Multiplex gene silencing technology for scalable in vivo cell and gene therapy (ANT)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Switzerland
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: CLOSED

Antion Biosciences is a Swiss biotech company pioneering a proprietary miRNA-based gene modulation platform. Unlike traditional gene editing tools, Antion’s synthetic miRNA (miRGE™) approach enables efficient, tunable, and multiplex silencing of multiple genes from a single construct, delivering increased safety, scalability, and physiological relevance. This platform is complementary and orthogonal to DNA-editing methods (e.g. CRISPR, TALENs, ZFN, etc) and addresses critical limitations around off-target risks, immunogenicity, and delivery complexity. Antion targets the rapidly expanding cell and gene therapy market, projected to grow from $25 billion in 2025 to over $117 billion by 2034, driven by a demand for safer, scalable in vivo gene modulation solutions. The company is actively expanding its portfolio to in vivo engineering and has validated its platform through key partnerships, including Allogene Therapeutics, Penn Medicine, and PolTREG. Antion’s business model focuses on licensing, co-development, and direct partnerships, offering ready-to-deploy platform assets for single or multiplexed indications. Advanced AI design tools and a modular innovation engine underpin continuous development of novel miRNAs. Ongoing R&D programs and preclinical data demonstrate superior safety and efficacy, positioning the platform as a next-generation solution for oncology, immunology, regenerative medicine, and rare diseases. Thanks to its strong and diverse IP portfolio for rapid market entry and risk mitigation. Antion’s financial strategy includes staged revenue (from licensing fees to royalties and milestone payments) with scalability supported by broadening therapeutic applications and global expansion. In summary, Antion Biosciences delivers a disruptive, validated gene modulation technology poised to unlock transformative therapies, break down bottlenecks in gene silencing, and capture growing commercial opportunities in the evolving cell and gene therapy market.

Keywords: cell and gene therapy,in vivo engineering,gene silencing
Foundation AGI model for Industrial Robots (FAIR)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Today's automation solutions excel in structured environments but fail in complex and variable situations, significantly impacting industries like manufacturing and warehouse logistics. Robotics has traditionally focused on pick-and-place tasks because they provide a foundational basis for automation. Mastering these tasks allows for the generalization of solutions to other industrial automation applications. However, automating unstructured and unpredictable environments remains a significant challenge, requiring greater flexibility and adaptability in the supply chain. To disrupt the automation industry SICS is developing next-generation AI that addresses the limitations of today’s AI and solves key problems of: 1) Lack of robustness; 2) Lack of structured world model; 3) Lack of online interaction; 4) Lack of multi-step reasoning and planning. At best, the step-by-step reasoning in today’s AI is based on statistical pattern recognition rather than true reasoning . SICS's objective is to build a foundation model for robots, a more general AI that learns online and can control any type of robot hardware independent of geometry and kinematics, using any type of sensors and data sources as input. This will allow robots to “learn by doing” and have an inherent continuous improvement where every interaction with the world is training the system, much like human learning. With support and financing from EIC, we will be able to boost the development and lower the threshold for VCs to co-invest alongside EIC. The funding will also play an important role in independent external quality approval and a granted application will serve as a due diligence that increases the trust and lower the threshold for investors to engage.

Keywords: foundation model,robotics,artificial general intelligence,automation
Ascent to the Kingdom: The Eucharistic Ethics of Maximos Confessor (AKEEMC)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Attracting and mobilising the best talents
Destination: Attracting and mobilising the best talents
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Serbia
Call: ERA Fellowships (HORIZON-WIDERA-2023-TALENTS-02, 2023)
Start date: 2024-06-01
End date: 2026-05-31
Duration (months): 24.0
Total project cost (EUR): 140187.84
EU funding (EUR): 140187.84
Participants: 1
Project status: SIGNED

The main thesis of my postdoctoral project, entitled Ascent to the Kingdom: The Eucharistic Ethics of Maximos Confessor, is that Maximos subscribes to a kind of eucharistic ethics in which the human is called to offer back the gift of being in the form of gratitude (eucharistia) culminating in the perfection of being, the unificatory state of deification. I argue that Maximos’ ethics is fundamentally an ethics of Oneness, of the progressive realization – on a personal and cosmic level – of the fundamental unity at the heart of reality. This unitary ethics is summed up in the inseparability of virtue & contemplation. Together, these practices work to overcome the inner fragmentation of the self and the outer divisions of the world introduced by ignorance and sin. All the virtues – be it humility, forbearance, detachment, charity, love, fasting, contemplative prayer, vigils, worship – represent means of overcoming the instability of a life centred upon the finite self (the ego), leading to a more grounded God-centred life. The ethical life, in essence, represents the overcoming of divisions and the progressive (re)unification of self and world culminating in union with Christ and the Trihypostatic God who alone is One. The inherently unificatory practice of the virtues (as manifold expressions of love) is corroborated by contemplative insight into the oneness of God, nature, and the human person. Virtue and contemplation culminate in the unity of divine-human love (agapē).

Keywords: patristics,ethics,neoplatonism,maximus confessor,asceticism,contemplation,mysticism,anthropology,orthodox theology,philosophy,history of ideas,the virtues
Smart Response sELf-desInfected biobAsed NanoCoatEd surfaces for healthier environments. (RELIANCE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Industry
Destination: Increased Autonomy in Key Strategic Value Chains for Resilient Industry
Action type: Research and Innovation actions
Countries involved: Spain,Luxembourg,Türkiye,Belgium,Switzerland,Finland,France,Greece,Italy,Bulgaria
Call: Antimicrobial, Antiviral, and Antifungal Nanocoatings (RIA) (HORIZON-CL4-2021-RESILIENCE-01, 2021)
Start date: 2022-06-01
End date: 2026-05-31
Duration (months): 48.0
Total project cost (EUR): 4875571.25
EU funding (EUR): 4875569.0
Participants: 15
Project status: SIGNED

RELIANCE project aims to design and develop smart response self-disinfectant antimicrobial nanocoatings based y a new range of smart antimicrobial nanoparticles. Such nanoparticles will consist of mesoporous silica nanoparticles with metallic copper in their structure, modified with biobased bioactive compounds: Antimicrobial peptides (AMP’s) based on protein containing waste streams, and essential oils (EOs) coming from non-edible plants. The antibacterial action of these additives will be adjusted to the specific application, according to the dosages and durability requirements. In this way, two alternatives to incorporate the bioactive compounds will be considered: - The incorporation of the biobased EO into the porous substrate, to allow a controlled release (T or pH) of the bioactive compounds to the environment, - The attachment of the AMP to the nanoparticles surface, to allow a long-term action of the bioactive compound to the environment. RELIANCE project combines contact killing and leachable antibacterial actions ascribed to the additive with the non-sticking action due to the coatings formulation, thus providing an integral holistic solution to antimicrobial problems on different surfaces. The nature of the coatings, their characteristics (hydrophobicity and surface roughness) and their application methods (direct deposition by cold-atmospheric plasma, high throughput spraying or selective digital printing) will be specifically designed to allow not only the microbial repelling action, but also the adhesion of the coatings to different substrates commonly found in our living environments, such as metals, plastics or textiles, and to maximize their durability (in terms of performance and antibacterial properties). Beyond the present-day possibilities of conventional chemicals, sustainability and eco design criteria will be considered in the selection of the bioactives, and on the development of the nanocoatings.

Keywords: nanoparticles,sustainability,circular economy,anti microbial
Ubiquitin-Proteasome System crosstalk with Metabolism (UPSmeetMet)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Molecules of Life: B iological  Mechanisms , Structures  and Functions
Panel description: For all organisms : Molecular biology , biochemistry, structural biology, molecular biophysics , synthetic and chemical biology, drug design, innovative methods and modelling
Countries involved: Germany
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 2089688.0
EU funding (EUR): 2089688.0
Participants: 1
Project status: SIGNED

Cellular metabolites are essential components of life processes, and their import, biosynthesis, and enzymatic conversion are regulated by a wealth of pathways. The ubiquitin-proteasome system (UPS) plays a major role in ensuring that key metabolic regulators are maintained at proper levels, to control concentrations of ions, carbohydrates, amino acids, cofactors, and lipids. In particular, the activities and localization of critical ubiquitination enzymes (E3 ligases) and the proteasome must be tightly regulated to ensure that degradation is restricted to proteins that are unwanted, superfluous, or toxic, while sparing those proteins needed for ongoing metabolic functions. Nonetheless, we have limited knowledge of fundamental structural and cellular mechanisms underlying this regulation, and the extent of crosstalk between E3 ligases and metabolic signals. The main aim of this proposal is to decipher molecular principles underlying crosstalk between ubiquitination and metabolites at large. By using time-resolved cryo EM, single-molecule biophysics, cell-based mutagenesis screens and functional studies, we will provide insights into how E3 ligases regulate key mediators of glucose, ion, and lipid homeostasis (Aim 1). To further increase knowledge of the breadth and depth of crosstalk between metabolic pathways and the UPS, we will use our toolkit of E3 ligases and probes to define regulatory interactions between a wide swath of metabolites and E3 ligases, and to identify E3s activated upon switches in metabolic conditions (Aim 2). Moreover, we will explore how E3 ligases and proteasomes are reorganized at an ultrastructural level inside cells to respond to starvation or nutrient-rich conditions (Aim 3). Taken together, these interdisciplinary approaches will establish a framework to translate conceptual and technical advances across molecular, structural, cell biological and systems levels, to broadly illuminate coordination between metabolic signals and the UPS.

Keywords: ubiquitin e3 ligase ubiquitin proteasome system molecular mechanisms of signalling processes metabolic enzymes metabolites
Concepts, tools and applications for community-driven bioeconomy development in European rural areas (SCALE-UP)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Circular economy and bioeconomy sectors
Action type: Coordination and support actions
Countries involved: Germany,France,Spain,Croatia,Poland,Austria,Netherlands,Sweden
Call: Mainstreaming inclusive small-scale bio-based solutions in European rural areas (HORIZON-CL6-2021-CIRCBIO-01, 2021)
Start date: 2022-09-01
End date: 2025-08-31
Duration (months): 36.0
Total project cost (EUR): 2999887.5
EU funding (EUR): 2999887.5
Participants: 9
Project status: SIGNED

The overall goal of SCALE-UP is to support regional multi-actor partnerships, consisting of private businesses, governments and policymakers, civil society organisations, and researchers in identifying and scaling-up innovative and sustainable bio-based value chains that build on regional resources. Through its approach, SCALE-UP will adapt, implement and evaluate tools to help regional actors to overcome the apparent bottlenecks towards fully exploiting bioeconomy potentials in their region. A four phase methodology will: i) establish existing knowledge and set the stage for further research, as well as creating six regional platforms with local stakeholders; ii) facilitate cross-regional transfer of knowledge and demand-driven capacity building, and provide support to multi-actor partnerships to carry out market assessments and business model designs; iii) create a pan-European ‘Community of Practice’ to facilitate sharing good practices and lessons learned across European regions; and iv) disseminate and exploit project results in collaboration with key stakeholders. In addition to the focus on increasing capacity and knowledge on the bioeconomy among relevant actors in the regions, a key feature of SCALE-UP is the business development programme to be applied by the local communities. With an emphasis on the principles of co-creation, transparency and open innovation, the project will provide advisory support to innovators and regional stakeholders to assess market conditions, elaborate business plans and identify compatible funding sources for 12 bio-based solutions.

Keywords: rural development,bio based business models,small scale solutions
Cyber securitY tooLbox for COnnected MEdical Devices (CYLCOMED)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Maintaining an innovative, sustainable and globally competitive health industry
Action type: Research and Innovation actions
Countries involved: Slovenia,Germany,Switzerland,Italy,Spain,Belgium,Portugal
Call: Enhancing cybersecurity of connected medical devices (HORIZON-HLTH-2022-IND-13, 2022)
Start date: 2022-12-01
End date: 2025-11-30
Duration (months): 36.0
Total project cost (EUR): 3489625.01
EU funding (EUR): 3489625.0
Participants: 11
Project status: SIGNED

Accelerated digitalisation in health sector brings opportunities for cost-effective and efficient delivery of personalised care, through medical devices (including software) connected to IT networks and increasingly combined with novel technologies (AI, cloud computing, blockchain or 5G networks) and simultaneously Europe is witnessing an increase in the complexity and sophistication of attacks threatening such critical infrastructure. CYLCOMED addresses the overall ambitious goal of strengthening the cybersecurity of connected, in vitro diagnostic and software as medical devices (CMDs, IVDs, SaMD), maintaining their performance and safety for patients and preserving or enhancing the confidentiality, integrity and availability of private data they exchange or allow to be remotely accessed and focusing on humans operating the technology as the weakest link in the chain for security and privacy, with training and awareness measures tailored to healthcare staff needs. It does so by enabling adoption by all ecosystem stakeholders of technologically sovereign and trustworthy cybersecurity methodologies and toolboxes for connected medical devices and the environments in which they are managed and operate (platforms), complemented with fit-for-purpose guidance covering identifed risks and gaps. It will further deliver: (i) risk assessment framework with risk benefit analyses schemes and (ii) toolbox addressing cybersecurity risks and gaps in connected medical devices;(iii) assessment and extension of baseline standards, best practices and guidelines covering challenges for CMDs including SW, making them fit for purpose when used in conjunction with novel technologies; (iv) demonstrations and case studies in relevant on premise hospital scenarios (COVID-19 patients monitoring) and remote telemonitoring scenarios improving the life of paediatric patients. CYLCOMED has 9 partners from 7 EU Member States and 1 associate partner from Switzerland and a duration of 36 months.

Keywords: risk assessment and risk management,ai,telemedicine,toolbox,case studies,regulatory compliance,guidelines,training,standards
NanoConfinement effects from Capacitors to Catalysis (NanoC3)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Netherlands
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-04-01
End date: 2026-03-31
Duration (months): 24.0
Total project cost (EUR): 187624.32
EU funding (EUR): 187624.32
Participants: 1
Project status: SIGNED

The societal transformation to renewable energy necessitates more efficient ways to store energy. This can be achieved by direct energy storage in batteries or supercapacitors (SCs) or by using electrocatalysis to convert energy, e.g., to green hydrogen. The efficiency of such processes can be enhanced, by increasing the surface of the electrode. Increase of the surface can be achieved by introducing pores into the electrodes. However, in recent years the porosity has reached the nanometre scale. At this scale the pores become so small that the interfacial layer known as double-layer, as well as ions at the surface, are confined. In NanoC3, we aim to understand the effect of confinement of ions and of the double-layer on charge storage and hydrogen production. For this purpose, we will analyze materials, with unprecedented control of the pore size, provided from collaborations with material scientists, using innovative surface science techniques. These measurements are enabled by the expertise of the ER in microcalorimetry and of the host institution in spectroscopy and electrocatalysis. To study confinement of the double-layer, gold electrodes with tuneable slits will be provided by Serge Lemay (Twente, NL). Gold is a well-studied model electrode to investigate the double-layer and hydrogen evolution, allowing for comparison of the results with literature data. Theoretical calculations will be performed by Alexei Kornyshev (Imperial College, UK). To obtain the even smaller pore sizes necessary to study ion confinement, MoS2 and V2O5 electrodes will be provided by S. Fleischmann (KIT, GER). These layered materials can be tuned by intercalating molecular pillars, leading to an increase of the interlayer spacing. MoS2 can be used to substitute the expensive Pt in the hydrogen evolution, while V2O5 is a well-researched SC, exhibiting ion confinement. In summary, the goal of NanoC3 is to advance the field of electrocatalysis in a new and yet unexplored direction.

Keywords: nanoconfinement,hydrogen evolution,charge storage,electrocatalysis